2024 AACR Annual Meeting: Regeneron's Linvoseltamab Phase 1/2 trial reveals high response rates deepening over time in pre-treated multiple myeloma patients.
Regeneron Pharmaceuticals announced pivotal data at AACR Annual Meeting 2024 from the Phase 1/2 LINKER-MM1 trial of linvoseltamab, an investigational bispecific antibody targeting multiple myeloma. The data demonstrated high response rates that deepened over time in heavily pre-treated patients. Linvoseltamab is designed to bridge BCMA on multiple myeloma cells with CD3-expressing T cells, facilitating T-cell activation and cancer-cell killing.
April 07, 2024
4 Articles